Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Clinical and Molecular Characteristics of Patients with Fascio-scapulo-humeral Dystrophy 1 (FSHD 1): The First Cohort Investigating the Genotype-phenotype Characteristics of FSHD 1 Patients in Turkey
Neuromuscular and Clinical Neurophysiology (EMG)
P3 - Poster Session 3 (5:30 PM-6:30 PM)
11-019
Due to  technical difficulties, molecular diagnosis could only be performed in  limited centers in the world so far.  As the treatment trials have accelerated lately the value of molecular diagnosis has become more important. 

In this study, the results of the first cohort that investigated the molecular and clinical characteristics of Fascio-Scapulo-Humeral Dystrophy-1 (FSHD-1) patients in Turkey will be presented.

Using  'Molecular Combing' (MC) method, D4Z4 repeat units (RU) of 53 patients were analyzed. FSHD clinical score (CS) test was used in clinical examination.

A reduced of D4Z4 RU (2-9) was detected in a total of 48 index patients. Then 5 more family members with reduced RU (2-9)and  FSHD phenotype were added to  study. Familial cases comprised 52% of all cases.

Group with low (0-3) CS: The RU was ≥5 (5-9) in 11 patients. The mean age at onset was 27.6±6.9 years, the most prominent initial complaints were asymmetric arm weakness and scapula dislocation (9/11), facial muscle weakness (2/11). All patients exhibited typical FSHD clinic.

Group with medium (4-10) CS: The RU was ≥2 (2-9) in 36 patients. The mean onset age was 17.4±14.3 years. Four patients had tongue weakness/atrophy, 2 patients had deltoid atrophy, and 2 patients had quadriceps muscle weakness with preserved tibialis anterior muscle.

Group with high (11-15) CS:  8 reduced RU were detected in 1 patient (6/53, 11%), remaining 5 patients showed 3-4 reduced RU. The mean onset age was 15.9±13.2 years. One patient had tongue weakness and atrophy.

The correlation between the reduced number of RU and disease severity was similar to the previous reports. Additionally, the distribution of familial and de novo FSHD cases was almost equal in our study, which does not fully overlap with the literature information. In larger cohort studies, the phenotype-genotype correlation in our country will be determined more clearly.

Authors/Disclosures
Gulshan Yunisova, MD (Koç University Hospital, Muscle Disease Center)
PRESENTER
Dr. Yunisova has nothing to disclose.
Serpil Eraslan (Koc University Hospital) No disclosure on file
Sahin Avci No disclosure on file
Ilker Eren No disclosure on file
Mehmet Demirhan (Koc University School of Medicine) No disclosure on file
Hulya Kayserili (Kocc University School of Medicine (KUSoM) Medical Genetics Department) No disclosure on file
Piraye Oflazer No disclosure on file